AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company engaged in insurance fraud in China, leading to legal exposure and potential harm to its business activities in the region [1]. Group 1: Allegations - The complaint alleges that during the class period from February 23, 2022, to December 17, 2024, AstraZeneca made materially false and misleading statements [1]. - Specific allegations include that AstraZeneca engaged in insurance fraud in China, which resulted in the detention of the AstraZeneca China President by law enforcement [1]. - The lawsuit claims that AstraZeneca understated its legal risks, and the revelations could materially harm the company's business activities in China [1]. Group 2: Class Action Details - Shareholders who purchased shares of AstraZeneca during the specified class period are encouraged to register for the class action, with a deadline of February 21, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].